Want to see HK:0719 full AI Analyst Report?
Top Page
Shandong Xinhua Pharmaceutical Company Limited Class H
(0719)
Select Model
Select Model
Rating:56Neutral
Price Target:
HK$5.50
▼(-17.54% Downside)
Action:Reiterated
Date:10/30/26
The score is driven primarily by mid-quality financial performance: the company remains profitable with manageable leverage and positive cash flow, but TTM revenue and margins have weakened and free cash flow momentum is negative. Technicals further weigh on the rating as the stock trades below key moving averages with negative MACD. Valuation is a modest offset due to the ~3.19% dividend yield, but the high ~36.99 P/E limits upside without a fundamental rebound.
Positive Factors
Manageable leverage
The company remains profitable while debt-to-equity has generally stayed near 0.24–0.34, indicating leverage is manageable. A growing equity base provides financial capacity to sustain operations and pursue investment through the next several quarters.
Negative Factors
Revenue slowdown
The TTM revenue pullback interrupts the company’s prior multi-year growth pattern and signals weaker recent demand or business momentum. If sustained, slower sales would reduce operating leverage and make it harder to rebuild earnings growth over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Manageable leverage
The company remains profitable while debt-to-equity has generally stayed near 0.24–0.34, indicating leverage is manageable. A growing equity base provides financial capacity to sustain operations and pursue investment through the next several quarters.
Read all positive factors
Shandong Xinhua Pharmaceutical Company Limited Class H (0719) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$8.28B
Dividend Yield3.22%
Average Volume (3M)1.73M
Price to Earnings (P/E)37.2
Beta (1Y)0.60
Revenue Growth-0.52%
EPS Growth-37.60%
CountryHK
Employees7,240
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)0.33
Shares Outstanding195,000,000
10 Day Avg. Volume242,780
30 Day Avg. Volume1,727,243
Financial Highlights & Ratios
PEG Ratio-0.36
Price to Book (P/B)0.78
Price to Sales (P/S)0.47
P/FCF Ratio9.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.81
Revenue Forecast (FY)HK$9.22B
Shandong Xinhua Pharmaceutical Company Limited Class H Business Overview & Revenue Model
Company Description
Shandong Xinhua Pharmaceutical Company Limited develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People's Republic of China, the Americas, Europe, and internationally. The company offers antipyretic...
Shandong Xinhua Pharmaceutical Company Limited Class H Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
72
Positive
Cash Flow
60
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.02B | 8.75B | 8.47B | 8.10B | 7.50B | 6.56B |
| Gross Profit | 1.43B | 1.64B | 2.04B | 2.32B | 2.04B | 1.77B |
| EBITDA | 440.38M | 988.87M | 1.11B | 1.09B | 1.01B | 908.67M |
| Net Income | 227.94M | 289.89M | 470.02M | 496.51M | 411.06M | 348.55M |
Balance Sheet | ||||||
| Total Assets | 8.81B | 9.19B | 9.02B | 8.29B | 8.27B | 7.33B |
| Cash, Cash Equivalents and Short-Term Investments | 1.19B | 1.40B | 1.25B | 918.33M | 1.16B | 744.66M |
| Total Debt | 894.24M | 1.31B | 1.35B | 1.08B | 1.38B | 1.04B |
| Total Liabilities | 3.22B | 3.73B | 3.80B | 3.51B | 3.92B | 3.68B |
| Stockholders Equity | 5.34B | 5.21B | 4.99B | 4.55B | 4.13B | 3.47B |
Cash Flow | ||||||
| Free Cash Flow | 307.79M | 418.13M | 155.19M | -59.85M | 513.48M | 9.89M |
| Operating Cash Flow | 390.87M | 533.73M | 367.61M | 265.28M | 758.24M | 259.12M |
| Investing Cash Flow | -70.46M | -103.50M | -212.21M | -305.11M | -228.90M | -237.69M |
| Financing Cash Flow | -351.09M | -291.13M | 184.78M | -196.11M | -130.66M | -139.73M |
Shandong Xinhua Pharmaceutical Company Limited Class H Technical Analysis
Negative
6.67
Price Trends
5.63
Negative
5.76
Negative
6.08
Negative
Market Momentum
-0.09
Positive
39.63
Neutral
38.97
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0719, the sentiment is Negative. The current price of 6.67 is above the 20-day moving average (MA) of 5.53, above the 50-day MA of 5.63, and above the 200-day MA of 6.08, indicating a bearish trend. The MACD of -0.09 indicates Positive momentum. The RSI at 39.63 is Neutral, neither overbought nor oversold. The STOCH value of 38.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0719.
Shandong Xinhua Pharmaceutical Company Limited Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | HK$12.54B | 9.38 | 25.10% | 5.11% | 15.05% | 20.58% | |
74 Outperform | HK$26.72B | 16.30 | 11.32% | 6.71% | -9.56% | -23.22% | |
68 Neutral | HK$29.12B | 6.18 | 7.92% | 5.17% | 7.94% | 52.83% | |
57 Neutral | HK$35.32B | 14.74 | 5.57% | 6.71% | 6.00% | -23.05% | |
56 Neutral | HK$8.28B | 37.23 | 4.32% | 3.22% | -0.52% | -37.60% | |
52 Neutral | HK$6.76B | 18.42 | 5.03% | 1.50% | 29.68% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:0719
Shandong Xinhua Pharmaceutical Company Limited Class H
5.35
-1.42
-20.94%
HK:0874
Guangzhou Baiyunshan Pharmaceutical Holdings Company
12.86
-5.10
-28.41%
HK:1513
Livzon Pharmaceutical Group
23.18
-5.02
-17.81%
HK:0460
Sihuan Pharmaceutical Holdings Group
0.73
-0.75
-50.71%
HK:3320
China Resources Pharmaceutical Group Ltd.
4.64
-0.11
-2.26%
HK:1681
Consun Pharmaceutical Group Ltd.
15.25
1.00
7.00%
Shandong Xinhua Pharmaceutical Company Limited Class H Corporate Events
Shandong Xinhua Pharma Posts Lower Nine‑Month Profit Despite Asset Growth
Oct 28, 2026
Shandong Xinhua Pharmaceutical Company Limited, a Hong Kong‑listed Chinese drug maker, reports its consolidated results under China Accounting Standards for Business Enterprises and maintains compliance with Hong Kong’s listing and ins...
Xinhua Pharmaceutical’s Nimodipine Tablets Clear China’s Generic Consistency Review
Oct 19, 2026
Shandong Xinhua Pharmaceutical announced that its nimodipine tablets have passed China’s generic drug quality and efficacy consistency evaluation, following approval from the National Medical Products Administration. The product, already app...
Shandong Xinhua Pharma Calls EGM to Approve New Executive Director
Oct 16, 2026
Shandong Xinhua Pharmaceutical Company Limited has convened an extraordinary general meeting for 10 November 2026 in Zibo, Shandong Province, to seek shareholder approval for the appointment of Mr. Liu Weimin as an executive director. His proposed...
Shandong Xinhua Pharmaceutical Sets Board Meeting to Review Nine-Month Results
Oct 14, 2026
Shandong Xinhua Pharmaceutical Company Limited has scheduled a board meeting to be held in Zibo, Shandong, on 28 October 2026 at 9:30 a.m. The directors will review and approve the unaudited financial results of the company and its subsidiaries fo...
Shandong Xinhua Pharma Proposes Board Appointment of Senior Economist Liu Weimin
Oct 9, 2026
Shandong Xinhua Pharmaceutical Company Limited has proposed the appointment of Mr. Liu Weimin, a 47-year-old senior economist with extensive enterprise management experience at controlling shareholder Hualu Holding Group, as an executive director....
Xinhua Pharmaceutical Wins Approval for Sacubitril Valsartan Tablets in China
Oct 8, 2026
Shandong Xinhua Pharmaceutical Company Limited has received a Drug Registration Certificate from China’s National Medical Products Administration for its sacubitril valsartan sodium tablets, a Class 4 chemical prescription drug. The approval...
Shandong Xinhua Subsidiary Wins Approval for Donepezil Orally Disintegrating Tablets in China
Sep 18, 2026
Shandong Xinhua Pharmaceutical announced that its wholly owned subsidiary, Shandong Zibo Xincat Pharmaceutical, has obtained a drug registration certificate from China’s National Medical Products Administration for its 5mg Donepezil Hydrochl...
Shandong Xinhua Pharmaceutical Wins Approval for New Oral Solution
Sep 18, 2026
Shandong Xinhua Pharmaceutical Company Limited has obtained a Drug Registration Certificate from China’s National Medical Products Administration for its magnesium sulfate, sodium sulfate and potassium sulfate concentrate oral solution, clas...
Shandong Xinhua Pharma Wins Approval for Levocarnitine Oral Solution
Sep 18, 2026
Shandong Xinhua Pharmaceutical Company Limited, a Chinese producer of chemical prescription drugs, has expanded its product portfolio with a new oral formulation. The company focuses on domestic drug production and compliance with national pharmac...
Shandong Xinhua Subsidiary Wins Key Generic Consistency Approval for Azithromycin
Aug 31, 2026
Shandong Xinhua Pharmaceutical has announced that its wholly owned subsidiary, Shandong Zibo Xincat Pharmaceutical, received approval from China’s National Medical Products Administration confirming that its azithromycin tablets have passed ...
Shandong Xinhua Wins NMPA Approval for Dapoxetine Tablets
Aug 28, 2026
Shandong Xinhua Pharmaceutical has obtained a Drug Registration Certificate from China’s National Medical Products Administration for its domestically produced Dapoxetine Hydrochloride Tablets, a Class 4 chemical prescription drug. The appro...
Shandong Xinhua Pharmaceutical Releases Unaudited 2026 Interim Results
Aug 25, 2026
Shandong Xinhua Pharmaceutical Company Limited, a PRC-based drug manufacturer, operates from Zibo City in Shandong Province and is listed on both the Hong Kong and Shenzhen stock exchanges. The company’s dual listing structure in H and A sha...
Xinhua Pharmaceutical Wins China Approval for Dapagliflozin Tablets
Aug 21, 2026
Shandong Xinhua Pharmaceutical Company Limited has received a Drug Registration Certificate from China’s National Medical Products Administration for its dapagliflozin tablets. The approval covers domestically produced 5mg and 10mg prescript...
Shandong Xinhua Pharmaceutical Schedules Board Meeting to Review 2026 Interim Results
Aug 11, 2026
Shandong Xinhua Pharmaceutical Company Limited has scheduled a board meeting to be held at its conference room in Zibo, Shandong, on 25 August 2026. The meeting will review and approve the unaudited interim results for the six months ended 30 June...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.